Circulating Biologically Active Adrenomedullin Predicts Organ Failure and Mortality in Sepsis

키워드

참고문헌 (34)

1. Singer M, "The third international consensus definitions for sepsis and septic shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
2. Vincent JL, "The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction", failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine, 1996, pp.22, 707~710
3. Vincent JL, "Use of the SOFA score to assess the incidence of organ dysfunction", failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine, 1998, pp.26, 1793~1800
4. Moreno R, "The use of maximum SOFA score to quantify organ dysfunction", failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM, 1999, pp.25, 686~696
5. Fan SL, "Diagnosing sepsis-The role of laboratory medicine", Clin Chim Acta, 460, pp.203~210 (2016)
6. Chan D, "Case studies and clinical correlations", pp.285~296 (2016), Springer International Publishing
7. Hamid SA, "Adrenomedullin : regulator of systemic and cardiac homeostasis in acute myocardial infarction", Pharmacol Ther, 105, pp.95~112 (2005)
8. (2018)[URL]
9. Chen S, "Association of adrenomedullin gene polymorphisms and blood pressure in a Chinese population", Hypertens Res, 36, pp.74~78 (2013)
10. Nagaya N, "Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure", Circulation, 101, pp.498~503 (2000)
11. Eto T, "Regulation of production and secretion of adrenomedullin in the cardiovascular system", Regul Pept, 112, pp.61~69 (2003)
12. Geven C, "Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis", Front Immunol, 9, pp.292~ (2018)
13. Jozine M. ter Maaten, "Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure", European Journal of Heart Failure, 21(6), pp.732~743 (2019), Wiley[DOI]
14. Voors AA, "Adrenomedullin in heart failure : pathophysiology and therapeutic application", Eur J Heart Fail, 21, pp.163~171 (2019)
15. Weber J, "Sandwich immunoassay for bioactive plasma adrenomedullin", J Appl Lab Med, 2, pp.222~233 (2017)
16. Caironi P, "Circulating biologically active adrenomedullin(bio-ADM)predicts hemodynamic support requirement and mortality during sepsis", Chest, 152, pp.312~320 (2017)
17. Mebazaa A, "Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis : the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1(AdrenOSS-1)study", Crit Care, 22, pp.354~ (2018)
18. Geven C, "A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration(AdrenOSS-2)", BMJ Open, 9, pp.e024475~ (2019)
19. Rhodes A, "Surviving Sepsis Campaign : International guidelines for management of sepsis and septic shock : 2016", Crit Care Med, 45, pp.486~552 (2017)
20. Williams JM, "Review article : sepsis in the emergency department-Part 3 : treatment", Emerg Med Australas, 30, pp.144~151 (2018)
21. "Sphingotest bio-ADM information sheet" (2018)[URL]
22. Simon TP, "Plasma adrenomedullin in critically ill patients with sepsis after major surgery : A pilot study", J Crit Care, 38, pp.68~72 (2017)
23. Marino R, "Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis", Crit Care, 18, pp.R34~ (2014)
24. Schefold JC, "Heart failure and kidney dysfunction : epidemiology, mechanisms and management", Nat Rev Nephrol, 12, pp.610~623 (2016)
25. Martin L, "The septic heart : current understanding of molecular mechanisms and clinical implications", Chest, 155, pp.427~437 (2019)
26. 양현석, "Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis", Annals of Laboratory Medicine, 36(6), pp.590~594 (2016), 대한진단검사의학회
27. Ponikowski P, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail, 18, pp.891~975 (2016)
28. Kremer D, "Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure", Eur J Heart Fail, 20, pp.1363~1365 (2018)
29. Self WH, "Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure", Am J Emerg Med, 34, pp.257~262 (2016)
30. Tolppanen H, "Adrenomedullin : a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock", Ann Intensive Care, 7, pp.6~ (2017)
31. Meeran K, "Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans : a pharmacokinetic study", J Clin Endocrinol Metab, 82, pp.95~100 (1997)
32. Mallamaci F, "Plasma adrenomedullin during acute changes in intravascular volume in hemodialysis patients", Kidney Int, 54, pp.1697~1703 (1998)
33. Valenzuela-Sánchez F, "New role of biomarkers : mid-regional pro-adrenomedullin, the biomarker of organ failure", Ann Transl Med, 4, pp.329~ (2016)
34. Elke G, "The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis – a secondary analysis of a large randomised controlled trial", Crit Care, 22, pp.79~ (2018)

관련 논문AI추천